Innovation RecognitionTerumo has been recognized for its innovative needle technology, making it a top choice for pharmaceutical packaging of popular GLP-1 weight loss drugs.

Market ExpansionThe joint venture with Weigao Blood Purification allows Terumo to tap into China's large market, potentially increasing its market presence.

Product AdvancementTerumo is following the market movement from predominantly glass-focused syringes to polymeric materials, bringing along multiple benefits including higher break resistance and less risk of reaction with drugs.

Bears Say

Growth OpportunitiesThe delay in the IPO of Weigao Blood Purification on the HKEX could be detrimental to Terumo, as the listing could boost growth.

Market ExpansionThe delay in the IPO of Weigao Blood Purification could be detrimental to Terumo, as the listing could boost growth.

Pricing PressureThere is a risk of price cuts for hemodialysis systems in China due to the country's Volume Based Procurement scheme.

Terumo News

Terumo Corporation Reports Strong Financial Growth

Terumo ( ($TRUMF) ) has released its Q2 earnings. Here is a breakdown of the information Terumo presented...

2M ago

Terumo’s Earnings Call: Record Growth Amid Challenges

Terumo (($JP:4543)) has held its Q2 earnings call. Read on for the main highlights of the call. During...

2M ago

Terumo Revises FY2025 Financial Guidance Amid Yen Depreciation

Terumo ( ($JP:4543) ) just unveiled an announcement. Terumo Corporation has revised its full-year financial guidance for the...

2M ago

Terumo Corporation Reports Strong Financial Growth and Increased Dividends

Terumo ( ($JP:4543) ) has provided an update. Terumo Corporation reported a 5.2% increase in revenue and a...

2M ago

Terumo (TRUMF) Q2 Earnings Cheat Sheet

Terumo (TRUMF) is scheduled to report 2nd quarter earnings on 11/12/2025, before the market opens. Regarding Q2 estimates,...

2M ago

Terumo Corporation Revises Shareholder Benefit Program to Boost Engagement

Terumo ( ($JP:4543) ) has issued an update. Terumo Corporation announced an amendment to its Shareholder Benefit Program,...

4M ago

Terumo Acquires OrganOx to Enter Organ Transplantation Sector

Terumo ( ($JP:4543) ) just unveiled an update. Terumo Corporation has announced its acquisition of OrganOx Limited for...

5M ago

Terumo Corporation Reports Modest Revenue Growth

Terumo ( ($TRUMF) ) has released its Q1 earnings. Here is a breakdown of the information Terumo presented...

5M ago

Terumo’s Earnings Call: Record Revenue Amid Challenges

Terumo (($JP:4543)) has held its Q1 earnings call. Read on for the main highlights of the call. During...

5M ago

Terumo Corporation Reports Increased Profits and Dividend Guidance

Terumo ( ($JP:4543) ) just unveiled an update. Terumo Corporation reported a modest increase in revenue for the...

5M ago

4543 FAQ

What was Terumo’s price range in the past 12 months?

Terumo lowest stock price was ¥2228.00 and its highest was ¥3122.00 in the past 12 months.

What is Terumo’s market cap?

Terumo’s market cap is ¥3.35T.

When is Terumo’s upcoming earnings report date?

Terumo’s upcoming earnings report date is Feb 05, 2026 which is in 25 days.

How were Terumo’s earnings last quarter?

Terumo released its earnings results on Nov 12, 2025. The company reported ¥23.76 earnings per share for the quarter, missing the consensus estimate of ¥24.499 by -¥0.739.

Is Terumo overvalued?

According to Wall Street analysts Terumo’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Terumo pay dividends?

Terumo pays a Semiannually dividend of ¥15 which represents an annual dividend yield of 1.22%. See more information on Terumo dividends here

What is Terumo’s EPS estimate?

Terumo’s EPS estimate is 22.47.

How many shares outstanding does Terumo have?

Terumo has 1,480,559,700 shares outstanding.

What happened to Terumo’s price movement after its last earnings report?

Terumo reported an EPS of ¥23.76 in its last earnings report, missing expectations of ¥24.499. Following the earnings report the stock price went up 1.032%.

Which hedge fund is a major shareholder of Terumo?

Currently, no hedge funds are holding shares in JP:4543

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Terumo

Terumo Corporation (4543) is a global medical technology company based in Japan, specializing in a wide range of healthcare products and services. The company operates primarily in two sectors: Medical Devices and Blood Management. Terumo's core offerings include vascular access devices, transfusion systems, and interventional cardiology products. The company is committed to advancing medical technology and improving patient outcomes through innovative solutions.

Terumo (4543) Earnings & Revenues

Historic Earnings Reports

4543 Company Deck

4543 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong revenue and profit growth, successful product launches, and a positive impact from strategic acquisitions. However, challenges such as tariff impacts, temporary costs, and lower than expected demand in certain areas balanced the overall outlook.View all JP:4543 earnings summaries